What's new? Log in Free sign up

IceCure Medical (ICCM)

Company Profile

Company profile

Ticker

ICCM

Exchange

Website

www.icecure-medical.com

CEO

Mr. Eyal Shamir

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Ares Capital • Becton, Dickinson and • Stryker • Boston Scientific • Solventum • Baxter International • Teleflex • Hercules Capital • ResMed ...

Former names

BAYVIEW ACQUISITION CORP

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

ICCM stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Report of Foreign Private Issuer

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Prospectus supplement for primary offering

Report of Foreign Private Issuer

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

Report of Foreign Private Issuer

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

Epoch Partner Investments Ltd

Epoch Partner Investments Ltd

ALPHA CAPITAL ANSTALT

Epoch Partner Investments Ltd

Epoch Partner Investments Ltd

ALPHA CAPITAL ANSTALT

ALPHA CAPITAL ANSTALT

Financial summary

Financial statements Chart ICCM financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

ICCM institutional ownership history Ownership history

43.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	5	9	-44.4%
Opened positions	1	3	-66.7%
Closed positions	5	8	-37.5%
Increased positions	0	1	EXIT
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	38.00 mm	127.38 mm	-70.2%
Total shares	24.35 mm	24.50 mm	-0.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Epoch Partner Investments	24.05 mm	$31.75 mm	0.0%
Alpha Capital Anstalt	290.38 k	$0.00	0.0%
Foundations Investment Advisors	10.00 k	$6.10 mm	0.0%
Efficient Wealth Management	2.50 k	$1.00 k	NEW
Bartlett & Co. Wealth Management	250.00	$153.00 k	0.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	0.00	-66.40 k	EXIT
Virtu Financial	0.00	-27.19 k	EXIT
Geode Capital Management	0.00	-25.56 k	EXIT
Kingdom Financial	0.00	-17.00 k	EXIT
Concurrent Investment Advisors	0.00	-10.00 k	EXIT
Efficient Wealth Management	2.50 k	+2.50 k	NEW
Proequities	0.00	0.00
Alpha Capital Anstalt	290.38 k	0.00	0.0%
Foundations Investment Advisors	10.00 k	0.00	0.0%
Epoch Partner Investments	24.05 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

IceCure Submits Filing For Regulatory Approval Of Its Next-Generation XSense Cryoablation System In Israel

Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing

IceCure Received Intention To Grant Notice From European Patent Office For "Cryogenic System Connector"

XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure

Press releases

From Benzinga Pro

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand CAESAREA,

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its categoryHands-on ProSense® training featured during the SIO Mini

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Seeks to expand regulatory approval in China where IceSense3 has already been approved CAESAREA, Israel, Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.